BUZZ - Reports suggest Lundbeck is interested in acquiring Xeris Pharmaceuticals, causing the company's stock to surge

September 29 - ** Xeris Biopharma XERS.O shares rose 2.8% to $10.08

** According to sources cited by Bloomberg, Lundbeck A/S HLUNa.CO has expressed (link) interest in acquiring Xeris Biopharma

** Lundbeck and Xeris Biopharma have not yet responded to Reuters' requests for comment

** The report stated that the Danish pharmaceutical company has been working with advisors to explore the possibility of acquiring Chicago-based Xeris

** As of the close of the previous trading day, XERS is up 27.9% so far this year

(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or not include required context, Reuters does not guarantee the accuracy of the automated translation and provides it for readers' convenience only. Reuters accepts no responsibility for any harm or loss arising from the use of the automated translation function.)